Biogen lures BMS exec to become its CMO
US biotech major Biogen (Nasdaq: BIIB) today revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs, effective October 28, 2024. Dr Quirk will report to Dr Priya Singhal, head of development at Biogen.
“At Biogen, scientific and medical leadership is the foundation for everything we do, and this is why we believe Dan will be a perfect fit to lead our Medical Affairs organization going forward,” said Dr Singhal, adding: “With his diverse background in medicine, public health, and business administration, and his extensive experience in medical affairs across both US and global markets, Dan is well-positioned to help drive our leadership forward as we expand further into neurology, immunology, and rare diseases.”
Business background
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze